PeptideDoc

PeptideDoc — Bayside, Queens · 4232 Francis Lewis Boulevard, Bayside, NY 11361

PeptideDoc Clinical Patient Education

Semaglutide: FDA-Approved Indications, Benefits & Care Process

Dr. Saul Maslavi, MD • Precision Peptide Therapy & Metabolic Care • Bayside, NY

A physician-supervised guide to how semaglutide works, who it is FDA-approved for, and the structured care journey followed at our Bayside, NY practice.

Schedule An Appointment Book Zoom RN Training
FDA-Approved503B SourcedMD-SupervisedPhysician NPI 1134137383
FDA-approved medication materials

Medical Director

Dr. Saul Maslavi, MD

Practice Location

4232 Francis Lewis Blvd, Bayside, NY 11361

Web Portal

https://peptidedoc.com/

Document ID

SEMA-CLIN-2026-V1

Clinical Overview

GLP-1 Receptor Agonist Physiology

Semaglutide is a selective, long-acting Glucagon-Like Peptide-1 (GLP-1) receptor agonist engineered to mimic endogenous incretin hormones. By binding and activating GLP-1 receptors in both peripheral metabolic tissues and central nervous system appetite centers, semaglutide orchestrates coordinated glycemic and metabolic regulation.

01

What is Semaglutide? Molecular Structure & Action

Derived structurally from native human GLP-1 with strategic amino-acid substitutions and a fatty diacid side-chain, semaglutide exhibits high affinity for serum albumin. This modification protects the molecule from rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), enabling prolonged receptor engagement and steady pharmacokinetic activity.

Glucose-Dependent Insulin Secretion

Enhances pancreatic beta-cell insulin release in response to elevated blood glucose levels while suppressing inappropriate postprandial glucagon secretion from alpha cells.

Gastric Emptying Modulation

Slows the rate at which food leaves the stomach, smoothing out post-meal glycemic excursions and extending signals of fullness.

Central Appetite & Satiety Signaling

Acts on key hypothalamic and brainstem nuclei governing energy homeostasis, reducing hedonic food drive and perceived hunger.

02

Primary FDA-Approved Indications

Semaglutide holds official U.S. Food and Drug Administration (FDA) approvals across distinct clinical contexts under physician oversight:

Type 2 Diabetes Mellitus Management

FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, as well as to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease.

Chronic Weight Management in Adults

FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) classified as obesity, or overweight in the presence of at least one weight-related comorbid condition (such as hypertension, type 2 diabetes, or dyslipidemia).

03

Cardiovascular & Metabolic Pleiotropic Benefits

Beyond glycemic control and weight reduction, clinical trials demonstrate broad systemic improvements in cardiometabolic markers:

Cardiovascular Risk Reduction

Significant risk reduction in major cardiovascular events among high-risk patients.

Blood Pressure & Lipid Optimization

Favorable shifts in systolic/diastolic blood pressure, triglycerides, and inflammatory markers.

Hepatic Metabolic Support

Reductions in hepatic steatosis and visceral adiposity associated with metabolic syndrome.

Individualized Prescribing & Compounding Standards

At PeptideDoc, treatment with semaglutide — whether FDA-approved commercial formulations or lawfully sourced compounded equivalents during official FDA drug shortages — is tailored exclusively following comprehensive diagnostic evaluation by Dr. Saul Maslavi, MD.

PeptideDoc Patient Care Journey

Safety Profile & Step-by-Step Patient Care Process

Structured Physician Supervision at the PeptideDoc Bayside Practice

Supervising MD

Dr. Saul Maslavi, MD

Care Model

Structured Evaluation

Clinic Location

Bayside, NY

Protocol Standard

FDA / cGMP Aligned

04

Comprehensive Safety Profile & Side-Effect Management

While semaglutide is clinically well-tolerated, patients must be informed of potential adverse reactions, contraindications, and mandatory monitoring requirements:

CategoryReported Adverse EffectsClinical Management & Precautions
Gastrointestinal (Most Common)Nausea, mild transient fullness, constipation, diarrhea, indigestion, or upper abdominal discomfort, particularly during early treatment phases.Gradual physician-guided titration, smaller frequent meals, and avoidance of high-fat or greasy items.
Systemic & MetabolicFatigue, mild headache, dizziness, or transient changes in resting heart rate.Hydration support, electrolyte balance, and regular vital sign checks during clinical reviews.
Strict ContraindicationsPersonal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); known hypersensitivity.Mandatory baseline endocrine and family history screening prior to authorizing any GLP-1 therapy.
05

The PeptideDoc Step-by-Step Patient Care Journey

Dr. Saul Maslavi, MD oversees a disciplined, safety-first clinical journey for every patient pursuing semaglutide therapy:

  1. 01Comprehensive Medical Evaluation & History Review

    In-person or authorized telehealth consultation with Dr. Saul Maslavi, MD to review metabolic health history, family cancer risk, medication reconciliation, and realistic wellness goals.

  2. 02Baseline Laboratory & Diagnostic Workup

    Targeted blood panels assessing HbA1c, fasting glucose, renal and hepatic function, lipid panel, thyroid biomarkers, and metabolic markers to confirm clinical candidacy.

  3. 03Personalized Prescription & Pharmacy Coordination

    Issuance of an individualized physician prescription fulfilled through FDA-registered 503A/503B compounding pharmacies or certified commercial distributors with cold-chain verified delivery.

  4. 04Supervised Titration & Nutritional Guidance

    Structured, gradual physician-managed advancement designed to maximize gastrointestinal tolerance while pairing peptide therapy with sustainable protein and lifestyle coaching.

  5. 05Ongoing Biometric Monitoring & Long-Term Maintenance

    Regular clinical touchpoints, body composition and lab tracking, and long-term metabolic preservation support at PeptideDoc Bayside.

Zoom RN injection training support

Zoom RN training for approved patients

RN training covers safe handling, storage, and technique education. Dosing decisions and medication eligibility remain physician-directed, and no compounded dosing instructions are provided.

Schedule a Semaglutide Consultation with Dr. Saul Maslavi, MD

Medical Director

Dr. Saul Maslavi, MD

Office Telephone

(718) 717-0003 Ext 7

Clinical Address

4232 Francis Lewis Blvd, Bayside, NY 11361

Official Website

https://peptidedoc.com/

Schedule An Appointment Book Zoom RN Training

FDA-approved medications only. MD consultation required in Bayside, Queens.

Continue learning

Medical Weight ManagementPatient answersTirzepatideFAQs